Country: Hungary
Language: English
Source: HMA (Heads of Medicines Agencies)
Leptosira Canicola, Leptosira Icterohaemorrhagiae 32 MALR
Pfizer Limited
QI07AB01
Suspension for injection
Leptospira
Dogs Non Food
2012-09-22
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Versican L3, suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Composition per 1 ml dose: ACTIVE SUBSTANCES (INACTIVATED): _Leptospira interrogans_ serovar Icterohaemorrhagiae_,_ strain MSLB 1008 ARL* titre ≥ 1:32 _Leptospira interrogans _serovar Canicola, strain MSLB 1010 ARL* titre ≥ 1:32 _Leptospira kirschneri _serovar Grippotyphosa_,_ strain MSLB 1009 ARL* titre ≥ 1:64 * Antibody micro agglutination -lytic reaction ADJUVANT: Aluminium hydroxide gel 1.8 - 2.2 mg EXCIPIENT: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection Pink colour with fine sediment 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunization of dogs to reduce clinical signs and infection caused by _Leptospira_ _interrogans_ serovars Canicola, Icterohaemorrhagiae and _Leptospira_ _kirschneri serovar _ Grippotyphosa. Reduction of urinary excretion of _Leptospira_ has not been shown. Onset of immunity: Immunity has been demonstrated from 4 weeks after the primary course Duration of immunity: At least one year following the primary vaccination course. 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES 3 None 4.5 SPECIAL PRECAUTIONS FOR USE _SPECIAL PRECAUTIONS FOR USE IN ANIMALS _ _ _ Only healthy animals should be vaccinated. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING Read the complete document